Skip to main content

Genetics in Medicine

  • ISSN: 1098-3600

Editor-In-Chief: Steiner

Next planned ship date: May 8, 2024

  • 5 Year impact factor: 8.9
  • Impact factor: 8.8

Genetics in Medicine (GIM) is an official journal of the American College of Medical Genetics and Genomics. The journal's mission is to enhance the knowledge, understanding, and… Read more

Subscription options

Next planned ship date:
May 8, 2024

Institutional subscription on ScienceDirect

Request a sales quote


Genetics in Medicine (GIM) is an official journal of the American College of Medical Genetics and Genomics. The journal's mission is to enhance the knowledge, understanding, and practice of medical genetics and genomics through publications in clinical and laboratory genetics and genomics, including ethical, legal, and social issues as well as public health. As genetics and genomics continue to increase in importance and relevance in medical practice, the journal will be an accessible and authoritative resource for the dissemination of medical genetic knowledge to all medical providers through appropriate original research, reviews, commentaries, standards, and guidelines. GIM encourages research that combats racism, includes diverse populations and is written by authors from diverse and underrepresented backgrounds.

In addition:

GIM does not publish case reports

Manuscripts reporting population level research carried out in predominantly or exclusively White populations will generally not be accepted without strong justification for lack of diversity in the population studied.

The significance of articles reporting data and/or observations from a limited geographic region is evaluated in the context of whether they are generalizable across relevant populations or whether they might fill a knowledge gap in populations that are underrepresented in genetics research or that experience health disparities.

Although cancer genetics is a focus, GIM discourages cancer genetics manuscripts with data limited to somatic and/or tumor genetics. Manuscripts with novel findings on non-germline genetics (for example, somatic [tumor] variation, CHIP [clonal hematopoiesis of indeterminate potential], somatic and constitutional mosaicism) that inform our understanding of germline risk may also be considered. Manuscripts reporting on circulating tumor DNA (ctDNA) or "liquid biopsy" are also generally not within the scope of GIM.

Manuscripts should not contain previously published material without appropriate permission.

GWAS studies are generally low priority for GIM.